(ASTROH) Aneurysmal Subarachnoid Hemorrhage Trial Randomizing Heparin: A Prospective, Randomized, Phase IIA Pilot Study of Unfractionated Heparin in aSAH
The primary objective of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous unfractionated heparin (LDIVH) infusion for the prevention of aneurysmal subarachnoid hemorrhage (aSAH) induced neurocognitive dysfunction and other delayed neurological deficits.
- 18 - 70 years old
- Disease: Subarachnoid Hemorrhage
- Disease type: Aneurysmal Subarachnoid Hemorrhage
For additional information about eligibility criteria, please contact the study coordinator Jessica Smith:
- Drug: Heparin
- Drug type: Anticoagulant
Full details regarding study procedures can be explained by the study coordinator Jessica Smith:
Can be done from home
KeywordsAneurysm in the brain, Aneurysm, Brain aneurysm repair, Subarachnoid hemorrhage
Principal InvestigatorAdam Polifka, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.